Alembic Pharmaceuticals Reports 21% Profit Surge in Q2 2025
Alembic Pharmaceuticals reported a significant 21% year-on-year rise in their consolidated net profit to Rs 185 crore for the second quarter ending September 2025, compared to Rs 153 crore in the previous year. Their revenue from operations also grew to Rs 1,910 crore, with notable growth in their US formulations business.
- Country:
- India
Alembic Pharmaceuticals has announced a commendable 21% increase in their consolidated net profit, reaching Rs 185 crore in the second quarter of 2025.
This rise is up from Rs 153 crore during the same period last year, showcasing robust business growth.
The company saw its operational revenue grow to Rs 1,910 crore, with the US formulations segment demonstrating significant sales growth. Shares of Alembic Pharma rose by 3.87%, closing at Rs 960.10 on the BSE.
Advertisement
ALSO READ
-
Glenmark Pharmaceuticals Eyes US Market with New Launch
-
Patanjali Foods Ltd Achieves 67% Net Profit Surge in Q2
-
Maruti Suzuki Q2 net profit rises 8 per cent to Rs 3,349 crore; total revenue up 13 per cent at Rs 42,344.2 crore: Co filing.
-
Shreeji Shipping Global reports Rs 80 cr net profit in H1
-
ITC Q2 consolidated net profit up 4.1 pc at Rs 5,187cr, revenue dips marginally
Google News